Global HCV Market Analyzed in New Renub Research Report Published at

25 Jan 2012 • by Natalie Aster

LONDON – The global hepatitis C virus (HCV) drug market reached USD 6 billion in 2011 and is anticipated to more than double its present figure by 2015. One of the main drivers lying behind this robust growth is the launch of novel premium-priced agents that are expected to increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients.

New market research report “Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016” prepared by Renub Research presents comprehensive analysis of the global hepatitis C virus drug market, highlighting key drivers and restraints as well as their impact on current and future market scenario. The study also features the prevalent competitive landscape, launched HCV drugs present and future performance, yet to be launched HCV drugs forecast. Furthermore, valuable insights into the pipeline products within the global hepatitis C sector are also provided.

The companies mentioned in the report include: Merck, Vertex Pharmaceuticals, Roche, Pharmasset, Anadys Pharmaceuticals.

Report Details:

Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
Published: January, 2012
Pages: 72
Price: US$ 975,00

More new market reports by the publisher can be found at Renub Research page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970